Key player · Company profile
Merck & Co., Inc.
Named as a key player in 495 of our reports, across 33 regions and countries.
Named as a key player in 495 of our reports, across 33 regions and countries.
2023–2033 CAGR · estimates
Australia 15
Brazil 15
Canada 15
China 15
Ecuador 15
Egypt 15
France 15
Germany 15
Hong Kong 15
India 15
Italy 15
Japan 15
Kenya 15
Malaysia 15
Mexico 15
New Zealand 15
Philippines 15
Russia 15
Saudi Arabia 15
Singapore 15
South Africa 15
Spain 15
Thailand 15
UAE 15
UK 15
US 15| Market | Category | World 2023 | CAGR |
|---|---|---|---|
| Oncology/Cancer Drugs | Pharmaceuticals | $177 Bn | 8.4% |
| Asthma & COPD Drugs | Pharmaceuticals | $49.5 Bn | 4% |
| Over The Counter (OTC) Vitamins and Minerals | OTC & Nutraceuticals | $32 Bn | 5.5% |
| HIV Drugs | Pharmaceuticals | $30 Bn | 5.8% |
| Contraceptives Drugs | Pharmaceuticals | $25.2 Bn | 6.8% |
| Over The Counter (OTC) Analgesics | OTC & Nutraceuticals | $22 Bn | 3.4% |
| Anti-Depressants Drugs | Pharmaceuticals | $18 Bn | 2.7% |
| Over The Counter (OTC) Sleep Aid Products | OTC & Nutraceuticals | $5.3 Bn | 4% |
| Over The Counter (OTC) Ophthalmic Drugs | OTC & Nutraceuticals | $3.6 Bn | 4.5% |
| Bone Cancer Diagnostic | Healthcare Services | $1.1 Bn | 7.4% |
| Vitamin B12(Cobalamin) | OTC & Nutraceuticals | $300 Mn | 5.5% |
| Alopecia areata | Healthcare Services | – | – |
| Alopecia Drugs (Hair Loss) | Pharmaceuticals | – | – |
| Anti-Venom | Pharmaceuticals | – | – |
| Atherosclerosis Drugs | Pharmaceuticals | – | – |
Named as key players in the same markets as Merck & Co., Inc. (number of shared markets).
Johnson & Johnson9 shared markets
Pfizer Inc.9 shared markets
AstraZeneca8 shared markets
Novartis AG8 shared markets
Sanofi5 shared markets
F. Hoffmann-La Roche Ltd4 shared markets
GlaxoSmithKline plc4 shared markets
Abbott Laboratories3 shared markets